Company: CERO
Filing Date: 2025-12-05
Form Type: S-1
Source: 0001213900-25-118817
Chunk: 444

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-12-05
Form: S-1
Chunk 444
---
 receive an aggregate fee equal to 6% of the gross proceeds received in the Offering and Jones will receive an aggregate fee equal to 3% of the gross proceeds received in the Offering. In addition, the Company agreed to reimburse the Placement Agent for its legal fees and expenses and other out-of-pocket expenses in an amount up to $ 85,000, non-accountable expenses of up to $ 25,000and has agreed to reimburse Jones for all reasonable and documented out-of-pocket fees and expenses, including but not limited to travel and other out-of-pocket expenses in an amount not to exceed $ 15,000. The Company’s directors and executive officers agreed not to offer, issue, sell, contract to sell, encumber, grant any option for the sale of or otherwise dispose of any shares of common stock or other securities convertible into or exercisable or exchangeable for common stock for a period of 90 days following the closing date of the Offering, which terms may be waived in the sole discretion of and without notice by the Placement Agent, subject to certain exceptions. In addition, the Company has agreed to not enter into variable rate financings for a period of 180 days following the closing date, subject to certain exceptions, or enter into any equity financings for a period of 60 days following the closing date, subject to certain exceptions. In connection with the Offering, the Conversion Price of the Series A Preferred Stock and Series C Preferred Stock reset to $ 39.60per share of Common Stock. On March 4, 2025, the Company’s Board of Directors granted directors, officers and employees options to purchase up to 20,313shares of common stock for $ 28.60per share. The grants have various vesting conditions, including time-based and performance-based terms. These stock options expire on March 4, 2035. On March 10, 2025, the Company redeemed 316shares of Series C Preferred Stock from certain investors for a cash payment of $ 395,000, or $ 1,250per share of Series C Preferred Stock. F-66 Up to 729,596,950 Shares of Common Stock CERO THERAPEUTICS HOLDINGS, INC. PRELIMINARY PROSPECTUS , 2025 PART II INFORMATION NOT REQUIRED IN PROSPECTUS Item 13. Other Expenses of Issuance and Distribution. The following table sets forth the estimated expenses to be borne by the registrant in connection with the securities being registered hereby.